Logo Logo

Category Archives: "Partners"

  1. Home
  2. Partners
  3. Page 2
Dec 12, 2022
A new patient assistance offering from Janssen
Partners
FOR INSURED PATIENTS WHO ARE FACING ACCESS AND AFFORDABILITY CHALLENGES Janssen believes that access and affordability challenges [...]
Elizabeth Porco
Read More
...285
0
Oct 19, 2022
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
INforMS, Partners
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
Elizabeth Porco
Read More
...291
0
Aug 16, 2022
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
INforMS, Partners
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Elizabeth Porco
Read More
...261
0
Apr 21, 2022
Janssen Pharmaceuticals U.S. transparency report
INforMS, Partners
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Elizabeth Porco
Read More
...269
0
Mar 29, 2022
Genentech premiers #MSVisibility 2022
INforMS, Partners
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Elizabeth Porco
Read More
...177
0
Mar 15, 2022
Sanofi’s 2022 annual pricing principles report
INforMS, Partners
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
Elizabeth Porco
Read More
...145
0
Feb 01, 2022
MR epectroscopic imaging may help better diagnose, treat multiple sclerosis
Partners
Magnetic resonance spectroscopic imaging (MRSI) performed at 7.0 T (7.0-T MRSI) could visualize pathologic findings of multiple sclerosis [...]
Elizabeth Porco
Read More
...148
0
Oct 01, 2021
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
INforMS, Partners
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
Elizabeth Porco
Read More
...257
0
Sep 30, 2021
NeurologyLive® announces the inaugural Giants of Multiple Sclerosis™ Program
CMSC PR, Partners
NeurologyLive® Announces the Inaugural Giants of Multiple Sclerosis™ Program The first annual award program will honor [...]
Elizabeth Porco
Read More
...406
0
Sep 22, 2021
The Brain Under Siege by Dr. Howard Weiner
MS Community, Partners
The CMSC and IOMSN are proud to announce the following: Dr. Howard L. Weiner has just written a new book on brain diseases called The [...]
Elizabeth Porco
Read More
...371
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM